FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea
The US Food and Drug Administration (FDA) recently approved tirzepatide, marketed as Zepbound, for moderate to severe obstructive sleep apnea (OSA) in adults with obesity, making it the first sleep apnea drug, according to an agency press release.
The US Food and Drug Administration (FDA) recently approved tirzepatide, marketed as Zepbound, for moderate to severe obstructive sleep apnea (OSA) in adults with obesity, making it the first sleep apnea drug, according to an agency press release.
